GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Smith & Nephew SN.L · GBp

Health Care · Health Care Equipment & Supplies · LSE · 🇬🇧 United Kingdom

FTSE 100

Compare

1,145.00p

+0.88%

Close of 20 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Smith & Nephew — daily LSE:SN

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Smith & Nephew on TradingView ↗
Market value
£9.62bn
Last close × shares
Volume
3m
Shares, 20 Nov 2026
Price to earnings
22.3
Dividend yield
2.49%

About Smith & Nephew

Its shares trade on LSE under the ticker SN.L. It has been listed since 13 August 1951. It is a member of the FTSE 100. In the fiscal year to 31 December 2025, it reported revenue of $6.29bn and net income of $638.1m. At that date it held total assets of $10.46bn and shareholders' equity of $5.29bn.

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire. The firm is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Figures and description from our data supplier, not checked against the company's own report.

More about Smith & Nephew →

Latest on Smith & Nephew

Our reporting

Next results

23 Feb 2027

Due on 23 Feb 2027. Analysts expect earnings of 0.44 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Smith & Nephew's ticker?

Smith & Nephew trades as SN.L on LSE, under ISIN GB0009223206.

What was Smith & Nephew's last closing price?

1,145.00p on 20 Nov 2026. The figure is in GBp and is never converted.

When does Smith & Nephew next report results?

Results are expected on 23 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.